B+L acquired by Valeant for $8.7 billion

Valeant Pharmaceuticals has entered into an agreement to acquire B+L for $8.7 billion, which includes $4.2 billion in debt. The deal is expected to close in Q3, and B+L will retain its name. » More

Bausch + Lomb settles with DOJ for Ista

B+L subsidiary Ista pleads guilty to conspiracy charges in anti-kickback case and agrees to pay $34M in civil and criminal fines. » More

EyeXam mobile app launches MVPs sponsored by industry leaders

Industry supports EyeXam mobile app to help users find local eyecare practitioners. » More

Under Pressure: Glaucoma Update – Register Now for a Great New Webinar Brought to you by the Optometry Times Editorial Team!

Allegro, Senju team up to develop treatment of vascular eye diseases

Senju acquired the rights to co-develop and market Allegro's integrin peptide therapy for intravitreal injection for vascular eye diseases such as AMD and diabetic macular edema. » More

Ocular health comparable to wearing no contact lens

Study shows that patients wearing 1-Day Acuvue TruEye lenses exhibit no clinically significant differences as compared to spectacle wearers after a year of lens wear. » More

Digital technology enhances examination, patient care, study shows

Study shows retinal imaging technology better detects retinal lesions compared with ophthalmoscopy. » More

NEW JOB OPPORTUNITIES

IA • Mauer Eye Center

CONNECT WITH Optometry Times

Join your colleagues in conversation, respond to hot-topic questions, and stay up to date on breaking news. Like and follow us today!

» Facebook

» Twitter